Ionis Pharmaceuticals to Host Q1 2026 Financial Results Webcast on April 29
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IONS?
Source: Newsfilter
- Webcast Announcement: Ionis Pharmaceuticals has announced a live webcast scheduled for April 29, 2026, at 8:30 a.m. Eastern Time, where it will discuss its first quarter financial results and key program advancements, aiming to enhance transparency for investors regarding its operations.
- Access to Webcast: Investors can access the webcast at https://ir.ionis.com/events-and-presentations/upcoming-events, with a replay available for a limited time post-event, ensuring that those unable to attend live can still obtain relevant information.
- Company Overview: For three decades, Ionis has focused on inventing medicines that improve the futures of patients with serious diseases, currently boasting marketed drugs and a leading pipeline in neurology and cardiometabolic diseases, reflecting its deep expertise in the biopharmaceutical sector.
- Innovation Leadership: As a pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies while advancing new approaches in gene editing, showcasing its profound understanding of disease biology and industry-leading technological capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 75.710
Low
65.00
Averages
92.67
High
110.00
Current: 75.710
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ionis Pharmaceuticals to Host Q1 2026 Financial Results Webcast on April 29
- Webcast Announcement: Ionis Pharmaceuticals has announced a live webcast scheduled for April 29, 2026, at 8:30 a.m. Eastern Time, where it will discuss its first quarter financial results and key program advancements, aiming to enhance transparency for investors regarding its operations.
- Access to Webcast: Investors can access the webcast at https://ir.ionis.com/events-and-presentations/upcoming-events, with a replay available for a limited time post-event, ensuring that those unable to attend live can still obtain relevant information.
- Company Overview: For three decades, Ionis has focused on inventing medicines that improve the futures of patients with serious diseases, currently boasting marketed drugs and a leading pipeline in neurology and cardiometabolic diseases, reflecting its deep expertise in the biopharmaceutical sector.
- Innovation Leadership: As a pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies while advancing new approaches in gene editing, showcasing its profound understanding of disease biology and industry-leading technological capabilities.
See More
A Doctor's Journey with His Son's Rare Disease
- Family Life Restructured: Dr. Joseph D'Orazio's family life was immediately altered upon learning of his son Gabe's diagnosis of Angelman syndrome, necessitating a complete reevaluation of daily routines and future plans to accommodate the realities of a special needs family.
- Emotional and Professional Intertwining: As a physician, facing his son's rare disease brought profound grief and a sense of loss of control, which transformed his emotional landscape and deepened his empathy and understanding for patients' suffering in his medical career.
- Patience and Growth: Gabe's condition taught Dr. D'Orazio invaluable lessons in patience and a reevaluation of life, enhancing his focus on emotional needs in medical practice and significantly improving his empathy as a physician.
- Community and Advocacy: By engaging with the Foundation for Angelman Syndrome Therapeutics, Dr. D'Orazio transformed feelings of isolation into connection, aiding other families and advancing research, showcasing the resilience and unity of families affected by rare diseases.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
Ionis Pharmaceuticals to Host Q1 2026 Financial Results Webcast on April 29
- Webcast Announcement: Ionis Pharmaceuticals has announced a live webcast scheduled for April 29, 2026, at 8:30 a.m. Eastern Time, where it will discuss its first quarter financial results and key program advancements, aiming to enhance transparency for investors regarding its operations.
- Access to Webcast: Investors can access the webcast at https://ir.ionis.com/events-and-presentations/upcoming-events, with a replay available for a limited time post-event, ensuring that those unable to attend live can still obtain relevant information.
- Company Overview: For three decades, Ionis has focused on inventing medicines that improve the futures of patients with serious diseases, currently boasting marketed drugs and a leading pipeline in neurology and cardiometabolic diseases, reflecting its deep expertise in the biopharmaceutical sector.
- Innovation Leadership: As a pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies while advancing new approaches in gene editing, showcasing its profound understanding of disease biology and industry-leading technological capabilities.
See More
A Doctor's Journey with His Son's Rare Disease
- Family Life Restructured: Dr. Joseph D'Orazio's family life was immediately altered upon learning of his son Gabe's diagnosis of Angelman syndrome, necessitating a complete reevaluation of daily routines and future plans to accommodate the realities of a special needs family.
- Emotional and Professional Intertwining: As a physician, facing his son's rare disease brought profound grief and a sense of loss of control, which transformed his emotional landscape and deepened his empathy and understanding for patients' suffering in his medical career.
- Patience and Growth: Gabe's condition taught Dr. D'Orazio invaluable lessons in patience and a reevaluation of life, enhancing his focus on emotional needs in medical practice and significantly improving his empathy as a physician.
- Community and Advocacy: By engaging with the Foundation for Angelman Syndrome Therapeutics, Dr. D'Orazio transformed feelings of isolation into connection, aiding other families and advancing research, showcasing the resilience and unity of families affected by rare diseases.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
